KemPharm Shares Trading Halted Ahead Of FDA Meet

KemPharm, Inc.

revealed that NASDAQ halted trading of its common stock on Thursday morning. The company was engaged in a clinical-stage specialty pharmaceutical in the discovery and development of proprietary prodrugs. The move followed after the Anesthetic and Analgesic Drug Products Advisory Committee and Drug Safety and Risk Management Advisory Committee of the FDA in the United States was slated to meet on Thursday. The meeting was for a public review of the data in the New Drug Application (NDA) for Apadaz (benzhydrocodone hydrochloride and acetaminophen), its investigational abuse-deterrent product candidate for the short-term management of acute pain. KemPharm pointed out the timelines that was established by the Prescription Drug User Fee Act (PDUFA) and said that the review of the NDA is expected to be complete by June 9, 2016. The company would host a conference call on Thursday at 6:15 p.m., ET to discuss the FDA's review of the Apadaz NDA. On Wednesday, the stock shed 5.55%.